New eczema drug aims to clear 75% of skin symptoms in 16 weeks
NCT ID NCT06094179
First seen Feb 17, 2026 · Last updated May 25, 2026 · Updated 15 times
Summary
This study tests a new medicine, BAT6026, in 33 adults with moderate to severe eczema that creams couldn't control. The goal is to see if it safely reduces skin redness, itching, and rash by at least 75% after 4 doses. Researchers compare different doses to a placebo to find the best dose for future larger studies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DERMATITIS, ATOPIC are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Jianzhong Zhang
Beijing, Beijing Municipality, China
Conditions
Explore the condition pages connected to this study.